MS Connection Blog


Promising Emerging Therapies Reported at MSPARIS2017

Blog Summary

‚ÄčIt’s been a real energy boost to attend this conference and to feel the buzz of 10,000 people talking about the latest groundbreaking MS research. The topic of emerging therapies is near and dear to me, since I work on the research team that sniffs out possible new approaches to treating MS and restoring function.
One of these is the first report from the trial of ibudilast in people with primary progressive or secondary progressive MS. This is an oral compound that has been used in Japan at a lower dose to treat asthma and post-stroke dizziness. It’s being tested to see if it can protect the nervous system from MS damage. In a phase 2 trial involving 255 people, ibudilast was found to slow the rate of brain atrophy (shrinkage) by 48% compared to a placebo. Finding a way to slow brain atrophy, which has been linked to cognitive and physical disability in MS, may significantly slow disease progression. The main side effects were nausea and skin rash...